DWDongwei Wang

Dongwei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dongwei Wang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table S3 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts

    by Adel T. Aref, Mohashin Pathan, Rosemary Habib, Peter G. Hains, Stephanie H.-S. Lim, Asim Anees, Li Ma, Judith Heads, Dongwei Wang, Clare Loudon, et al.

    List of the differentially abundant proteins across the High-risk vs Low-risk proteomic groups based on the “limma” analysis.

  • Open Access

    Supplementary Table S1 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts

    by Adel T. Aref, Mohashin Pathan, Rosemary Habib, Peter G. Hains, Stephanie H.-S. Lim, Asim Anees, Li Ma, Judith Heads, Dongwei Wang, Clare Loudon, et al.

    Number of mass spectrometry runs for each cohort and the number of identified peptides and proteins.

  • Open Access

    Supplementary Figures S1-S22 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts

    by Adel T. Aref, Mohashin Pathan, Rosemary Habib, Peter G. Hains, Stephanie H.-S. Lim, Asim Anees, Li Ma, Judith Heads, Dongwei Wang, Clare Loudon, et al.

    Supplementary Figure 1: CONSORT diagram. Supplementary Figure 2: Summary of the workflow to develop the proteomic-based risk score. Supplementary Figure 3: Evaluation of different cut-off points for the risk score in the training cohort. Supplementary Figure 4: The intensities of the six proteins included in the risk score among the normal (n = 67) and tumor (n = 175) tissue samples in the Training cohort. Supplementary Figure 5: The intensities of the six proteins included in the risk score among the relapse and non-relapse groups in the A) Training cohort (Cohort 1), B) The first validation cohort (Cohort 2), and C) The second validation cohort (Cohort 3). Supplementary Figure 6: The intensities of the six proteins included in the risk score in the three cohorts among (A-C) Tumor (T)-stage; (D-F) Nodal (N)-stage; (G-I) Tumor side and (J-L) Tumor grade. Supplementary Figure 7: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 1. Supplementary Figure 8: A receiver operating characteristic curve (ROC) showing the Area Under the Curve (AUC) of different models including clinical variables with and without the risk score in the training cohort (Cohort 1). Supplementary Figure 9: Kaplan-Meier analyses showing the association of proteomic risk score in Cohort 1 with the risk of recurrence among subgroup of patients with A) MSI High, B) MSI Stable, C) Left-sided tumor, D) Right-sided tumor, E) Adjuvant Chemotherapy, F) No Adjuvant Chemotherapy, G) Mucinous subtype, H) Non-mucinous subtype. MSI: Microsatellite Instability. Supplementary Figure 10: Kaplan-Meier analyses showing the association of adjuvant chemotherapy with risk of recurrence in A) Whole training cohort (Cohort 1), B) Among patients in the high proteomic risk group and C) Among patients in the low proteomic risk group. D) A nomogram including the proteomic risk score and clinical variables. Supplementary Figure 11: Pathway enrichment analysis related to the proteins differentially abundant in high- vs low-risk proteomic group. Supplementary Figure 12: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 2. Supplementary Figure 13: A receiver operating characteristic curve (ROC) showing the area under the curve (AUC) of different models including clinical variables with and without the risk score in the first validation cohort (Cohort 2). Supplementary Figure 14: Kaplan-Meier analyses showing the association of the proteomic risk score with risk of recurrence within subgroups of patients with A) High clinical risk (T4 and/or N2) or B) Low clinical risk (T1-3/N0-1) in Cohort. 2 Supplementary Figure 15: Risk of recurrence within Cohort 2 including the subgroups. Supplementary Figure 16: Risk of recurrence in Cohort 2 by adjuvant treatment regimen and duration. Supplementary Figure 17: Kaplan-Meier analyses showing the association of adjuvant chemotherapy regimens in Cohort 2 with risk of recurrence among the different subgroups of patients . Supplementary Figure 18: Prognostic value of the proteomic risk score in Cohort 3. Supplementary Figure 19: Association of the proteomic risk score and clinical variables with recurrence risk in Cohort 3. Supplementary Figure 20: A receiver operating characteristic curve (ROC) showing the Area under the curve (AUC) of different models, including clinical variables with and without the risk score in the second validation cohort (Cohort 3). Supplementary Figure 21: Risk of recurrence among different subgroups within Cohort 3. Supplementary Figure 22: Kaplan-Meier analyses of Cohort 3 showing the association of adjuvant chemotherapy with risk of recurrence.

  • Open Access

    Data from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts

    by Adel T. Aref, Mohashin Pathan, Rosemary Habib, Peter G. Hains, Stephanie H.-S. Lim, Asim Anees, Li Ma, Judith Heads, Dongwei Wang, Clare Loudon, et al.

    Purpose:Despite advances in colon cancer management, stage III disease lacks robust, clinically applicable prognostic biomarkers. We aimed to use proteomic profiling to provide a quantitative, tissue-based approach to improve recurrence risk stratification.Experimental Design:We performed data-independent acquisition mass spectrometric proteomic analysis of tumor samples from three independent stage III colon cancer cohorts (n = 759). Differential protein expression between tumor and matched normal adjacent tissue was analyzed in the training cohort (cohort 1) using the limma package, and a univariate Cox model identified candidate biomarker proteins. A risk score based on the levels of six proteins (ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, and CKAP4) was developed using multivariate Cox regression in the training cohort (n = 175) and validated in two external cohorts (cohort 2, n = 386; cohort 3, n = 198). Kaplan–Meier and multivariate Cox regression analyses assessed the prognostic value of the score for recurrence.Results:The six-protein risk score categorized patients in the training cohort as high- or low-risk for recurrence [hazard ratio (HR) 5.7, P < 0.001], and this was validated in the two separate cohorts (cohort 2: HR 1.8, P < 0.001; cohort 3: HR 1.8, P = 0.02). Integrating the proteomic score with clinical risk factors further enhanced prognostic accuracy (P < 0.001 in all three cohorts). The combined proteomic–clinical risk score consistently identified a subgroup of patients with very low recurrence risk across cohorts.Conclusions:The validated six-protein risk score improves prognostic stratification beyond standard clinical factors in stage III colon cancer, providing a robust framework for risk-adapted clinical investigation. Prospective, treatment-stratified clinical trials are warranted to determine whether this prognostic information can inform adjuvant therapy decision-making.

  • Open Access

    Supplementary Table S2 from Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts

    by Adel T. Aref, Mohashin Pathan, Rosemary Habib, Peter G. Hains, Stephanie H.-S. Lim, Asim Anees, Li Ma, Judith Heads, Dongwei Wang, Clare Loudon, et al.

    Missingness rate of the six proteins included in the risk score across the three cohorts.

  • Proteomics-Driven Risk Stratification in Stage III Colon Cancer: A Validated Prognostic Signature for Recurrence Prediction Using Three Independent Cohorts

    by Adel T. Aref, Mohashin Pathan, Rosemary Habib, Peter G. Hains, Stephanie H.-S. Lim, Asim Anees, Li Ma, Judith Heads, Dongwei Wang, Clare Loudon, et al.

    Purpose: Despite advances in colon cancer management, stage III disease lacks robust, clinically applicable prognostic biomarkers. We aimed to use proteomic profiling to provide a quantitative, tissue-based approach to improve recurrence risk stratification. Experimental Design: We performed data-independent acquisition mass spectrometric proteomic analysis of tumor samples from three independent stage III colon cancer cohorts (n = 759). Differential protein expression between tumor and matched normal adjacent tissue was analyzed in the training cohort (cohort 1) using the limma package, and a univariate Cox model identified candidate biomarker proteins. A risk score based on the levels of six proteins (ITIH1, PPIE, LTBP1, KPNA2, IGFBP7, and CKAP4) was developed using multivariate Cox regression in the training cohort (n = 175) and validated in two external cohorts (cohort 2, n = 386; cohort 3, n = 198). Kaplan–Meier and multivariate Cox regression analyses assessed the prognostic value of the score for recurrence. Results: The six-protein risk score categorized patients in the training cohort as high- or low-risk for recurrence [hazard ratio (HR) 5.7, P < 0.001], and this was validated in the two separate cohorts (cohort 2: HR 1.8, P < 0.001; cohort 3: HR 1.8, P = 0.02). Integrating the proteomic score with clinical risk factors further enhanced prognostic accuracy (P < 0.001 in all three cohorts). The combined proteomic–clinical risk score consistently identified a subgroup of patients with very low recurrence risk across cohorts. Conclusions: The validated six-protein risk score improves prognostic stratification beyond standard clinical factors in stage III colon cancer, providing a robust framework for risk-adapted clinical investigation. Prospective, treatment-stratified clinical trials are warranted to determine whether this prognostic information can inform adjuvant therapy decision-making.